Correspondence 0001193125-25-059980 from Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc.
Date: March 21, 2025 · CIK: 0001660334 · Accession: 0001193125-25-059980
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285719
Letter
Re: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-285719) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-285719) (the “ Registration Statement ”) to become effective on March 25, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Mark Ballantyne and Asheley Walker of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084 or mballantyne@cooley.com, or in his absence, Asheley Walker at (202) 842-7856 or awalker@cooley.com. [Signature page follows]
V ERRICA P HARMACEUTICALS I NC . 44 W. Gay St., Suite 400 West Chester, PA, 19380 March 21, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory
Very truly yours,
Verrica Pharmaceuticals Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP V ERRICA P HARMACEUTICALS I NC . 44 W. Gay St., Suite 400 West Chester, PA, 19380 March 21, 2025 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jason Drory Re: Verrica Pharmaceuticals Inc. Registration Statement on Form S-3 (File No. 333-285719) Request for Acceleration of Effective Date Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “ Registrant ”) hereby requests that the Securities and Exchange Commission (the “ Commission ”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-285719) (the “ Registration Statement ”) to become effective on March 25, 2025, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such other time as the Registrant or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Registrant hereby authorizes each of Mark Ballantyne and Asheley Walker of Cooley LLP to make such a request on its behalf. Once the Registration Statement has been declared effective, please confirm that event with Mark Ballantyne of Cooley LLP, counsel to the Registrant, at (703) 456-8084 or mballantyne@cooley.com, or in his absence, Asheley Walker at (202) 842-7856 or awalker@cooley.com. [Signature page follows] Very truly yours, Verrica Pharmaceuticals Inc. By: /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer cc: Jayson Rieger, Verrica Pharmaceuticals Inc. Christopher Hayes, Verrica Pharmaceuticals Inc. Mark Ballantyne, Cooley LLP Darren DeStefano, Cooley LLP Asheley Walker, Cooley LLP Signature Page to Company Acceleration Request – S-3